Literature DB >> 19294358

[Botulinum toxin treatment : therapy success in cases of depression and ongoing pension applications].

A Bachhuber1, G Reichel, M Doberenz, A Stenner, W Hermann.   

Abstract

INTRODUCTION: A discrepancy is often observed between the presence of botulinum toxin antibodies (Btx-Ab) and successful therapy. We studied whether depression and an ongoing pension application explain this contradiction.
METHOD: Sixty-five patients treated with Btx were questioned for subjective therapy failure (TF). The extensor digitorum brevis test (EDB test) indicated the presence of Btx-Ab. The Beck Depression Inventory and an exploration investigated for a depressive disturbance as well as an ongoing application for pension. We correlated the EDB test and the TF with a depressive disturbance and the wish for a pension.
RESULTS: Forty-three patients had TF, from which 22 Btx-Ab were positive. A depressive disturbance was found in 25 patients, and an ongoing application for pension in 21. The EDB test and TF did not however correlate TF with a depressive disturbance (P=0.003) and a pension desire (P=0.021). The TF mostly appeared at the beginning of treatment. DISCUSSION: A depressive disturbance and an ongoing application for a pension influence the therapeutic success more strongly initially than the development of Btx-Ab.
CONCLUSION: Besides Btx-Ab a depressive disturbance and an ongoing application for pension influences the therapeutic success.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294358     DOI: 10.1007/s00115-009-2690-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

1.  Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Uraiwan Jamnansiri
Journal:  Jpn J Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 2.447

2.  Relation between depression and anxiety in dystonic patients: implications for clinical management.

Authors:  E Moraru; P Schnider; A Wimmer; T Wenzel; P Birner; H Griengl; E Auff
Journal:  Depress Anxiety       Date:  2002       Impact factor: 6.505

3.  Development of resistance to botulinum toxin type A in patients with torticollis.

Authors:  P Greene; S Fahn; B Diamond
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

4.  Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.

Authors:  J Wissel; F Masuhr; L Schelosky; G Ebersbach; W Poewe
Journal:  Mov Disord       Date:  1997-09       Impact factor: 10.338

5.  Improving patient retention after botulinum toxin type A treatment.

Authors:  Lucille White; Elizabeth L Tanzi; Tina S Alster
Journal:  Dermatol Surg       Date:  2006-02       Impact factor: 3.398

6.  Antibody-induced failure of botulinum toxin type B therapy in de novo patients.

Authors:  Dirk Dressler; Hans Bigalke
Journal:  Eur Neurol       Date:  2004-10-12       Impact factor: 1.710

7.  Local botulinum toxin in the treatment of spastic drop foot.

Authors:  R Dengler; U Neyer; K Wohlfarth; U Bettig; H H Janzik
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

8.  Depression as measured by the DSM-III and the Beck Depression Inventory in an unselected adult population.

Authors:  J M Oliver; M E Simmons
Journal:  J Consult Clin Psychol       Date:  1984-10

9.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance.

Authors:  M Zuber; M Sebald; N Bathien; J de Recondo; P Rondot
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

10.  Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia.

Authors:  I M Skogseid; U F Malt; J Røislien; E Kerty
Journal:  Eur J Neurol       Date:  2007-08-15       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.